<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03572361</url>
  </required_header>
  <id_info>
    <org_study_id>V3-MOMMO-01</org_study_id>
    <nct_id>NCT03572361</nct_id>
  </id_info>
  <brief_title>Open Label Immunotherapy Trial for Breast Cancer</brief_title>
  <acronym>V3-MOMMO</acronym>
  <official_title>Open Label, One-arm, 3-month Study of Once-daily Tablet of V3-MOMMO as Immunotherapy of Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunitor LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immunitor LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase II will evaluate a new type of breast cancer immunotherapy based on a
      fundamentally new approach that has been successfully tested in a published clinical study of
      liver cancer. Investigators will test new tableted preparation, V3-MOMMO, obtained from
      hydrolyzed, inactivated blood and tumors of patients with breast cancer. Study will last 3
      months, 20 patients will be recruited, given one pill per day for three months. The primary
      clinical endpoint is effect on tumor size and burden after 3 months. Secondary endpoint will
      be effect on levels of tumor markers on monthly basis compared to baseline.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Worldwide, breast cancer is the number one cancer in women. It affects about 12% or 1.7 mln
      women worldwide. In Mongolia breast cancer is less common, occupies 5-th place by frequency
      in women, the incidence is 118 per 100,000 or 1,770 cases per year.

      Many different types of immunotherapy (especially checkpoint inhibitors) are being tested,
      but so far the successes have been insignificant, and serious side effects are frequent and
      unpredictable. This Phase II will evaluate a new type of breast cancer immunotherapy based on
      a fundamentally new approach that has been successfully tested in a published clinical study
      of liver cancer. Investigators will test new tableted preparation, V3-MOMMO, obtained from
      hydrolyzed, inactivated blood and tumor tissues of patients with breast cancer. Study will
      last 3 months, 20 patients will be recruited, given one pill per day for three months. The
      primary clinical endpoint is effect on tumor size and lymph nodes burden after 3 months.
      Secondary endpoint will be effect on levels of tumor markers (i.e., cancer antigen 15-3 (CA
      15-3), cancer antigen 27.29 (CA 27.29), and carcinoembryonic antigen (CEA) on monthly basis
      compared to baseline.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single arm, open label Phase II study in volunteers with breast cancer receiving daily dose of one pill of vaccine V3-MOMMO</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>No masking</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Effect on tumor size</measure>
    <time_frame>Monthly for 3 months</time_frame>
    <description>Changes in tumor size and lymph node burden (if any) compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect on level of serum tumor markers compared to baseline</measure>
    <time_frame>Monthly for three months</time_frame>
    <description>Commonly measured tumor markers associated with breast cancer, primarily CA 15-3, CA 27.29, and CEA, at baseline and at study termination</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>V3-MOMMO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral once daily pill of tableted vaccine (V3-MOMMO) containing pooled breast cancer antigens administered for 3 months in 20 volunteers with breast cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V3-MOMMO</intervention_name>
    <description>Tableted vaccine (V3-OVA) containing breast cancer antigens administered once daily for 3 months</description>
    <arm_group_label>V3-MOMMO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of breast cancer positive at least for CEA tumor marker at above
             normal threshold level

        Exclusion Criteria:

          -  Mastectomy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Majority of subjects with breast cancer are females</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aldar Bourinbayar, PhD, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Immunitor LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Galyna Kutsyna, MD, MD/PhD</last_name>
    <phone>+97695130306</phone>
    <email>kutsynagalyna@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aldar Bourinbayar, MD</last_name>
    <phone>+97695130306</phone>
    <email>marinatarakanovskaya@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Immunitor LLC</name>
      <address>
        <city>Ulaanbaatar</city>
        <country>Mongolia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aldar Bourinbaiar, MD</last_name>
      <phone>97695130306</phone>
      <email>aldar@immunitor.com</email>
    </contact>
    <contact_backup>
      <last_name>Marina Tarakanovskaya, MD</last_name>
      <email>marinatarakanovskaya@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Galyna Kutsyna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mongolia</country>
  </location_countries>
  <reference>
    <citation>Tarakanovskaya MG, Chinburen J, Batchuluun P, Munkhzaya C, Purevsuren G, Dandii D, Hulan T, Oyungerel D, Kutsyna GA, Reid AA, Borisova V, Bain AI, Jirathitikal V, Bourinbaiar AS. Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L. J Hepatocell Carcinoma. 2017 Apr 12;4:59-69. doi: 10.2147/JHC.S122507. eCollection 2017.</citation>
    <PMID>28443252</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 16, 2018</study_first_submitted>
  <study_first_submitted_qc>June 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2018</study_first_posted>
  <last_update_submitted>August 29, 2019</last_update_submitted>
  <last_update_submitted_qc>August 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

